Solution Nation Headquarters: Holon, Israel
Investor Relations: Yvonne Naughton, PhD / +1 (628) 241-0071 / ir@cgen.com
Description
Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors.
Industry
Life Sciences
Year Founded
Ownership
Public
Exchange / Symbol
NYSE: CGEN
Public Since
Chief Executive Officer
Chairman of the Board
Chief Financial Officer
Insider Ownership
Key Investors
Employee Count
Auditors
Investment Bankers
Law Firms
In the CEOs Own Words
Corporate Mission
Proudest Accomplishment
Next Milestone
Geographic Markets Served
Growth Drivers
Growth Headwinds
Indicia of Customer Satisfaction
Scalability
Workforce
Focus of Recruitment
Research and Development
Patent Count
Economic Sensitivity
Unique Metrics
Greatest Concern
Company Reports and Communications
SEC Filings
" target="_blank">